The purpose of PROMETCO is to provide real-world data on overall survival, treatment patterns, associated effectiveness and safety, and impact on patients with mCRC throughout the continuum of care1
CRC is a major public health burden2,3
FatCamera/E+ © Getty images
Published November 8, 2022
We are pleased to announce that the PROMETCO study recruitment period ended on October 31, 2022. We ended the recruitment period with a total of 738 patients enrolled in PROMETCO.
Published September 13, 2022
We are pleased to announce the recent data release from the PROMETCO study, presented at the ESMO Congress on Sunday, September 11.
To view an interactive version of these data on the PROMETCO microsite click here.
Published February 23, 2022
DiCE recently published a piece discussing their long-term collaboration with the PROMETCO initiative on patient engagement in real-world evidence studies. Read the piece here!
Published February 01 2022
Don't miss the recent treatment patterns data, available in an interactive format
ARG: Argentina, AUT: Austria, BEL: Belgium, CHE: Switzerland, CZE: Czech Republic, DEU: Germany, ESP: Spain, FRA: France, GRE: Greece, HRV: Croatia, HUN: Hungary, IRL: Ireland, ITA: Italy, NLD: Netherlands, PRT: Portugal, SVN: Slovenia, SWE: Sweden, UK: United Kingdom
Advances in treatment of mCRC in the past 15 years have improved patient survival to ~30 months based on data from RCTs4
Data from prospective real-world studies are lacking
PROMETCO aims to address this gap
Study objectives are to describe the following for mCRC patients in a real-world setting:
Treatment patterns for mCRC throughout the continuum of care
Effectiveness/safety of treatments in a real-world setting
Reasons for therapy discontinuations and choice of subsequent treatment
Adherence to national and ESMO guidelines
Healthcare resource utilization